EU Thumbs Up Signals First-Ever Approval For Leo’s Tralokinumab
UK Regulator Also Expected To Reach Decision On Approval Soon
Leo’s moderate-to-severe atopic dermatitis drug is set to be approved for the first time worldwide.
You may also be interested in...
Leo Pharma Strengthens Dermatology Position With Second Eczema Win
The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.
Leo CEO Bourdon Plots Return To Profit This Year
The Danish group has cut 300 jobs to shift to an external innovation sourcing model that will make Leo more competitive in the dermatology space and help it break even this year, CEO Christophe Bourdon tells Scrip.
Keeping Track: US FDA Says Yes To AZ’s Farxiga In CKD And ADC’s Zynlonta, But No To Leo’s Tralokinumab, Chiesi’s Pegunigalsidase
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker